MedTrace Logo

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes

NCT00600860 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2020-12-30

No results posted yet for this study

Summary

Study Objectives:

To collect and describe demographics, disease-management, and treatment outcomes of Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to the World Health Organization (WHO) criteria.

To perform observational studies concerning relevant scientific research questions in MDS using clinical data and biological samples, and to present relevant research outcomes in the fields of diagnosis and prognostication, health related quality of life issues, health economics, and risk stratification for newly developed classes of drugs.

To disseminate results of the studies to all stakeholders involved.

Conditions

  • Myelodysplastic Syndromes (MDS)

Interventions

OTHER

No interventions

Only registration of clinical practice

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • David Bowen, PhD · Leeds General Infirmary

  • Theo de Witte, Prof Dr · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • Austria
  • Croatia
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Serbia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600860 on ClinicalTrials.gov